Search Results
-
Description Rabbit PolyclonalApplications WB ICC/IF ELISA IHCReactivity Dm$449100 μg
-
Description Mouse MonoclonalApplications WB FCM IP Neutralizing /InhibitionReactivity Hu
Summary This antibody recognizes the consensus region 3 of the CD55 (DAF)
$459200 μg -
Description Mouse MonoclonalApplications IHC-Fr FCM IP Functional AssayReactivity Hu$419100 μg
-
Description Rat MonoclonalApplications WB FCM IP Neutralizing /InhibitionReactivity Ms$199200 μg
-
Description Rat MonoclonalApplications WB FCM IP Neutralizing /InhibitionReactivity Ms$419500 μg
-
Description Rat MonoclonalApplications IHC-Fr FCM IP Neutralizing /InhibitionReactivity Ms$199200 μg
-
Description Mouse MonoclonalApplications WB IHC-Fr FCM Neutralizing /InhibitionReactivity Hu$56950 μg
-
Description Armenian Hamster MonoclonalApplications WB IHC-Fr FCM Neutralizing /InhibitionReactivity Ms$419250 μg
-
Description Mouse MonoclonalApplications ELISA IHC Purification TurbidimetryReactivity Hu$419100 μg
-
Description Mouse MonoclonalApplications WB IHC-Fr FCM ELISAReactivity Hu
Summary This antibody recognizes the SC5b-9 complex of around 330 kDa. Both the classical and alternative complement pathways result in the formation of the cytolysis inducing C5b-9 complex. This complex is composed of 190 kDa C5b, which is bound to cells via 71 kDa C9. Sublytic assembly of C5b-9 on plasma membranes induces cell cycle activation and survival. The binding of C5b-9 to the 75 kDa S-protein (or vitronectin) in the fluid phase prevents C5b-9 from assembling on the plasma membrane, deactivating it and forming the SC5b-9 complex. SC5b-9 is stable in vitro and is, therefore, a reliable indicator of terminal complement pathway activation.
$939100 μg